Table 41: Clinical evidence profile: Comparison 3.2. Colistin inhalation powder versus colistin inhalation solution

Quality assessment							No of patients		Effect			
No of studies	**Design**	**Risk of bias**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**Colistin inhalation powder (COLI DPI)**	**Colistin inhalation solution (COLI neb)**	**Relative (95% CI)**	**Absolute**	**Quality**	**Importance**
Lung function: % mean change in FEV_1% predicted (follow-up: 4 weeks; range of scores: 0-100; Better indicated by lower values)												
1 COLO/DPI/02/05	randomised trials	serious[1]	no serious inconsistency	no serious indirectness	very serious[2]	none	16	15	-	MD 3.01 lower (18.71 lower to 12.69 higher)	VERY LOW	CRITICAL
Number of patients with 1 or more exacerbations												
NMA outcome												

Quality assessment							No of patients		Effect			
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Colistin inhalation powder (COLI DPI)	Colistin inhalation solution (COLI neb)	Relative (95% CI)	Absolute	Quality	Importance
Minor adverse events: vomiting (follow-up 8 weeks)												
1 COLO/DPI/02/05	randomised trials	serious[1]	no serious inconsistency	no serious indirectness	very serious[3]	none	2/16 (12.5%)	0/15 (0%)	RR 4.71 (0.24 to 90.69)	-	VERY LOW	IMPORTANT
Minor adverse events: productive cough (follow-up 8 weeks)												
1 COLO/DPI/02/05	randomised trials	serious[1]	no serious inconsistency	no serious indirectness	very serious[3]	none	2/16 (12.5%)	1/15 (6.7%)	RR 1.88 (0.19 to 18.6)	59 more per 1000 (from 54 fewer to 1000 more)	VERY LOW	IMPORTANT
Minor adverse events: chest discomfort (follow-up 8 weeks)												
1 COLO/DPI/02/05	randomised trials	serious[1]	no serious inconsistency	no serious indirectness	very serious[3]	none	4/16 (25%)	2/15 (13.3%)	RR 1.88 (0.4 to 8.78)	117 more per 1000 (from 80 fewer to 1000 more)	VERY LOW	IMPORTANT
Serious adverse events - AE: dyspnoea (follow-up 8 weeks)												
1 COLO/DPI/02/05	randomised trials	serious[1]	no serious inconsistency	no serious indirectness	very serious[3]	none	3/16 (18.8%)	4/15 (26.7%)	RR 0.7 (0.19 to 2.63)	80 fewer per 1000 (from 216 fewer to 435 more)	VERY LOW	IMPORTANT

Abbreviations: CI: confidence interval; FEV_1: forced expiratory volume in 1 second; MD: mean difference; RR: risk ratio
1 The quality of the evidence was downgraded by 1 as this is an open trial, and the randomization is unclear

3 The quality of the evidence was downgraded by 2 as the 95% CI crossed 2 clinical MIDs
3 The quality of the evidence was downgraded by 2 as the 95% CI crossed 2 default MIDs